Labcorp Holdings Inc.

LH Healthcare Diagnostics & Research

Labcorp Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.0 billion, up 7.25% from fiscal 2024.

Revenue
+6.92%
EPS
+3.18%
Free cash flow
+44.7%
Total debt
+3.21%

Quarter to September 2026, against a year earlier

363.82 0.52 +0.14%
Market cap
$29.5B
P/E
29.5×
Fwd P/E
26.7×
Dividend yield
0.79%
F-score
8/9
Altman Z
3.02
Beneish M
−2.55
Dividend safety
74/100

Labcorp Holdings Inc. 10-Q filed Oct 30, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed · accepted 4:11 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 5, 2026: 7 added · 3 removed · 32 modified; 29 with only figures updated

  1. Modified · FORWARD-LOOKING STATEMENTS

    31.business interruption, receivables impairment, delays in cash collection impacting days sales outstanding, supply chain disruptions or inventory obsolescence, increases in the Company’s material costs or other operating costs, or other impacts on the business due to natural disasters, adverse weather, chronic physical climate risks such as prolonged heat, drought, water stress, or rising energy costs, geopolitical events, public health crises, and other events beyond the Company’s control;

41 more changes in this Item, word by word, in Powerpack.